EN DE
Watch Medeze Group PCL for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medeze Group PCL (MEDEZE) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Medeze Group PCL stock THB 2.04, price THB 5.60, that is 63.6% below the price, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TH

MG Medeze Group PCL logo Thin data Nov 4, 2026

Medeze Group PCL

MEDEZE · BK
Very expensive, weak quality

Our calculation puts a fair price 64% below what the stock costs today.

Solidly profitable · 19.8% net margin (TTM)
Generates free cash flow over the last twelve months
Quality 45/100
Moderate moat 62/100 · thin data
Revenue last quarter 14% below a year ago.
Fair value 2.04 THB · Strongly overvalued
Weak Growth (revenue YoY −10.3 %/yr in THB)
2.9% dividend yield · Pays more than it earns
Trails peers (4/12)
Thin data
⚠ Small free float
Watch Medeze Group PCL for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

11.63 THB 5.60 THB Fair Value 2.04 THB Oct 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

25‑month range 5.60 THB – 11.63 THB · fair‑value band 1.99 THB – 2.16 THB · the 5.60 THB price screens above the 2.04 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Medeze Group PCL in your weekly email

Every Wednesday you see whether Medeze Group PCL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products.

Show moreShow less

It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells.

In addition, the company is involved in research, develops, and collects data on all types of human cellular activities and medical laboratory tests. Further, the company sells dietary supplements, cosmetics, and dermo cosmetics.

Medeze Group Public Company Limited was founded in 2010 and is based in Nakhon Pathom, Thailand.

Stock analysis

Medeze Group PCL (MEDEZE) currently trades at 5.60 THB, while our model-based Fair Value estimate is 2.04 THB, 64% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 4.36 THB per share, and 1 of the 15 models we run sit above the 5.60 THB price.

Bear case: the Dividend Discount group reads lowest at 1.19 THB, and 14 of the 15 models stay below the price. Data coverage for this calculation is low.

Scenario range: 1.99 THB (bear) to 2.16 THB (bull), the price of 5.60 THB sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Medeze Group PCL reported revenue of 744M THB in FY2025 versus 702M THB in FY2023, a compound +2.9%/yr. Reported net income was 196M THB in FY2025, compounding −9.5%/yr from FY2023.

Key figures

Market cap 6.0B THB (≈ $180M) Micro · P/E ratio 46.7 · P/S ratio 8.44 · EPS (TTM) 0.1200 THB · Dividend yield 2.9% · Net margin 19.8% · Return on equity 4.8% · Return on assets (EBIT) 15.7% (3-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (low confidence).

What moves the price

The share trades about 22% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −64%, MEDEZE screens richer than that median.

Fair Value models

Bear 1.99 THB Fair Value 2.04 THB Bull 2.16 THB
Price 5.60 THB · Downside -63.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 1.99 THB 2.04 THB 2.16 THB 69
Owner Earnings 1.56 THB 1.66 THB 1.81 THB 68
EPV 2.34 THB 2.47 THB 2.58 THB 68
All 15 models by family
DCF Models
Owner Earnings 1.56 THB 1.66 THB 1.81 THB 68
Earnings-Based
Graham-Dodd 1.25 THB 1.53 THB 1.72 THB 61
EPV 2.34 THB 2.47 THB 2.58 THB 68
Dividend Discount
Gordon GGM 1.07 THB 1.14 THB 1.25 THB 63
DDM Multi-Stage 1.07 THB 1.23 THB 1.42 THB 61
Multiples
P/E Multiple 3.03 THB 4.05 THB 5.06 THB 63
P/S Multiple 1.83 THB 2.44 THB 3.05 THB 58
P/B Multiple 9.16 THB 12.21 THB 15.27 THB 55
EV/EBIT 3.90 THB 4.81 THB 5.72 THB 63
EV/EBITDA 3.79 THB 4.66 THB 5.52 THB 64
EV/Revenue 2.64 THB 3.27 THB 3.89 THB 52
Asset-Based
NCAV (Graham) 0.7800 THB 1.19 THB 1.48 THB 52
Economic Profit
Residual Income 1.99 THB 2.04 THB 2.16 THB 69
ROIC Compounder 2.34 THB 2.47 THB 2.58 THB 64
Growth Earnings
Growth-Adj P/E 2.14 THB 3.06 THB 3.97 THB 61

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 43
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 28
Do the profits arrive as real cash?
Financial strength 97
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 83
How calm the share price moves, does not count
Price momentum 27
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 13/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

MEDEZE screens overvalued: fair value 64% below the price. Compare with HCA Healthcare, Inc →

Compare Medeze Group PCL with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks

Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Bottom 25%
Fair Value upside −63.6% · Bottom 25%
Profitability
Return on equity (12 months) 4.8% · Below median
Return on assets 5.7% · Above median
Net margin (12 months) 19.8% · Top 25%
Operating margin (12 months) 26.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −13.8% · Bottom 25%
Dividend yield (12 months) 2.9% · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 46.7× · Priciest 25%
P/B 2.07× · Pricier than median
P/S (12 months) 8.44× · Priciest 25%
EV/EBITDA 22.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)19 · sector 32
HEALTH (low debt)0 · sector 90
DIVIDEND (yield)57 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $23.40 $46.55 +99% vs MEDEZE
Aier Eye Hospital Group 300015 ¥9.01 ¥10.88 +21% vs MEDEZE
DaVita Inc DVA $191.35 $218.90 +14% vs MEDEZE
HCA Healthcare, Inc HCA $494.99 $547.34 +11% vs MEDEZE
Tenet Healthcare Corporation THC $283.33 $279.20 −1% vs MEDEZE
The Ensign Group ENSG $181.08 $140.09 −23% vs MEDEZE
Encompass Health Corporation EHC $137.54 $94.81 −31% vs MEDEZE
Fresenius SE FRE €52.48 €34.77 −34% vs MEDEZE
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,446 ₹5,234 −38% vs MEDEZE
Dr. Sulaiman Al Habib Medical Services Group 4013 215.00 SAR 109.45 SAR −49% vs MEDEZE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medeze Group PCL: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medeze Group PCL Fair Value". https://www.fairvalue-calculator.com/stock/MEDEZE

Frequently asked questions

Is Medeze Group PCL (MEDEZE) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 2.04 THB versus a price of 5.60 THB, about 64% lower (overvalued).
What is the fair value of MEDEZE?
Our model-based fair value for Medeze Group PCL is 2.04 THB (as of Nov 4, 2026), built from audited fundamentals. The current price: 5.60 THB.
What is the quality score of MEDEZE?
Medeze Group PCL has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medeze Group PCL (MEDEZE)?
Our model-based price target is the fair value of 2.04 THB (as of Nov 4, 2026) from 15 valuation models. Cautious scenario 1.99 THB, optimistic scenario 2.16 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Medeze Group PCL stock forecast for 2026?
Our models put fair value at 2.04 THB, about 64% lower versus a price of 5.60 THB (overvalued). Cautious scenario 1.99 THB, optimistic scenario 2.16 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Medeze Group PCL (MEDEZE)?
Medeze Group PCL reported trailing-twelve-month revenue of about 714M THB (latest available figure, as of Nov 4, 2026).
Does Medeze Group PCL pay a dividend?
Medeze Group PCL currently shows a dividend yield of 2.86% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Medeze Group PCL (MEDEZE) and when is the ex-dividend date?
Medeze Group PCL pays a dividend of 0.16 THB per share a year, a dividend yield of 2.9%. The last ex-dividend date was Apr 29, 2026. The payout ratio is 133% of earnings. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Medeze Group PCL (MEDEZE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medeze Group PCL it is 2.04 THB per share (as of Nov 4, 2026), against a price of 5.60 THB. It is the blended result of 15 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Medeze Group PCL stock overvalued or undervalued in 2026?
As of Nov 4, 2026, MEDEZE trades above its calculated fair value: price 5.60 THB, fair value 2.04 THB, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDEZE?
No. The price is what the market pays today (5.60 THB); the fair value is what the company's own numbers justify (2.04 THB). For Medeze Group PCL the two are 3.56 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Medeze Group PCL worth?
The market values Medeze Group PCL at about 6.0B THB (market capitalisation, as of Nov 4, 2026). Per share that is 5.60 THB; our models calculate a fair value of 2.04 THB per share.
What do the bullish and bearish scenarios say about MEDEZE?
Our models span a range for Medeze Group PCL: cautious scenario 1.99 THB, base 2.04 THB, optimistic 2.16 THB per share (as of Nov 4, 2026, price 5.60 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDEZE?
Medeze Group PCL trades at a price-to-earnings ratio of 46.7 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2.04 THB is built from several models across several years. Other multiples: P/B 2.1, P/S 8.4, EV/EBITDA 22.8.
How solid is the balance sheet of Medeze Group PCL (MEDEZE)?
Balance-sheet figures for Medeze Group PCL (as of Nov 4, 2026): return on equity 4.8%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is MEDEZE from its 52-week high?
Medeze Group PCL trades at 5.60 THB, about 22% below its 52-week high of 7.21 THB and at the low of 5.60 THB (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 2.04 THB is for.
Which stocks are comparable to Medeze Group PCL?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medeze Group PCL stock attractive at the current price?
The data as of Nov 4, 2026: price 5.60 THB, calculated fair value 2.04 THB (−64%), Quality Score 45/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDEZE calculated?
We run Medeze Group PCL through 15 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2.04 THB builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Medeze Group PCL itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medeze Group PCL (MEDEZE)?
The closing price on Nov 6, 2026 was 5.60 THB. Our model-based fair value is 2.04 THB, about 64% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medeze Group PCL right now?
The price sits above even our optimistic bull case (2.16 THB). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (1.99 THB to 2.16 THB), unusually little disagreement for a valuation.

Key figures of Medeze Group PCL

How large is the market capitalisation of Medeze Group PCL (MEDEZE)?
The market capitalisation of Medeze Group PCL is 6.0B THB (≈ $180M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medeze Group PCL (MEDEZE)?
The price-to-sales ratio of Medeze Group PCL is 8.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medeze Group PCL (MEDEZE)?
Earnings per share at Medeze Group PCL are 0.1200 THB (price ÷ EPS = P/E 46.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Medeze Group PCL (MEDEZE)?
The dividend yield of Medeze Group PCL is 2.9% (payout 133%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Medeze Group PCL (MEDEZE)?
The net margin of Medeze Group PCL is 19.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medeze Group PCL (MEDEZE)?
The return on equity (ROE) of Medeze Group PCL is 4.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medeze Group PCL (MEDEZE)?
On an EBIT basis the return on assets of Medeze Group PCL is 15.7% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medeze Group PCL (MEDEZE)?
The operating margin of Medeze Group PCL is 26.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medeze Group PCL (MEDEZE)?
Revenue at Medeze Group PCL is growing −13.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medeze Group PCL (MEDEZE)?
Earnings per share at Medeze Group PCL are growing −26.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Medeze Group PCL (MEDEZE) generate?
The free cash flow of Medeze Group PCL is −17.1M THB (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Medeze Group PCL in the live analysis

One click puts Medeze Group PCL on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.